Autres langues Exact Sciences Corporation

Actions

EXAS

US30063P1057

Temps réel estimé Cboe BZX Autres places de cotation 21:18:18 29/04/2024			Varia. 5j.	Varia. 1 janv.
58,85 ^USD	0,00%		-5,66%	-20,41%

15/04	Exact Sciences Corporation annonce des changements au niveau de la direction	CI
11/04	Exact Sciences signe un accord d'échange de dette et un placement de billets convertibles	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Exact Sciences Corporation announced that it has received $266.75 million in funding	17/04
Sector Update: Health Care Stocks Advance Premarket Monday	15/04
Exact Sciences Names Aaron Bloomer CFO	15/04
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer	15/04
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024	15/04
Exact Sciences Corporation Announces Executive Changes	15/04
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes	11/04
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes	11/04
Exact Sciences Corporation announced that it expects to receive $266.8 million in funding	10/04
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024	08/04
Exact Sciences Schedules First Quarter 2024 Earnings Call	08/04
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment	04/04
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer	01/04
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	28/03
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	28/03
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner	27/03
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study	13/03
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer	07/03
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing	05/03
EXACT SCIENCES LAUNCHES RISKGUARD HEREDITARY CANCER TEST IN THE UNITED STATES	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Exact Sciences Corporation

Actions

EXAS

US30063P1057

Autres langues

Filtres